Abstract:Myocardial infarction (MI) and osteoporotic fracture (Fx) are leading causes of morbidity and mortality worldwide, and there is epidemiological evidence linking their incidence, suggesting possible crosstalk. MI can exacerbate underlying atherosclerosis through sympathetic nervous system activation and β adrenoreceptor-mediated release of hematopoietic stem cells (HSCs), leading to monocytosis. We hypothesized that this same pathway may initiate systemic bone loss following MI, since osteoclasts differentiate from monocytes. In this study, MI was performed in 12-week-old male mice (n=24), and mice were randomized to treatment with a β-adrenergic receptor antagonist (SR 59230A) or no treatment for 10 days post-operatively; additional mice (n=21, treated and untreated) served as un-operated controls. Bone mineral density (BMD), bone mineral content (BMC), and body composition were quantified at baseline and 10 days post-MI using DXA; at 10 days post-MI circulating monocyte and neutrophil levels were quantified, and the L5 vertebral body and femur were analyzed with micro-computed tomography. We found that MI led to increases in circulating monocyte and neutrophil levels, but contrary to our initial hypothesis, β-antagonist treatment further increased circulating monocytes compared to untreated mice. BMD and BMC of MI mice decreased at the femur and lumbar spine (−6.9% femur BMD, -3.5% lumbar BMD); β-antagonist treatment diminished this bone loss response (−5.3% femur BMD, -1.2% lumbar BMD). Similarly, trabecular bone volume was decreased in MI mice compared to control mice, and this bone loss was partially attenuated by β-antagonist treatment. These results suggest that MI leads to bone loss at both the axial and appendicular skeleton, and that the sympathetic nervous system may be a modulator of this response. This study is the first to mechanistically show bone loss following an ischemic injury; these findings suggest that bone loss and increased fracture risk may be important clinical co-morbidities following MI or other ischemic injuries.

Region-specific sympatho-adrenergic regulation of specialized vasculature in bone homeostasis and regeneration

Type H Vessels in Osteogenesis, Homeostasis, and Related Disorders

Systemic Bone Loss Following Myocardial Infarction in Mice is Mitigated by Treatment with a β3 Adrenergic Receptor Antagonist

Sympathetic β1-adrenergic signaling contributes to regulation of human bone metabolism.

Type H blood vessels in bone modeling and remodeling

Regulatory role of sympathetic nervous system-adrenergic receptor on bone remodeling

Unique bone marrow blood vessels couple angiogenesis and osteogenesis in bone homeostasis and diseases

Targeting type H vessels in bone‐related diseases

Targeted inhibition of osteoclastogenesis reveals the pathogenesis and therapeutics of bone loss under sympathetic neurostress

Motivating role of type H vessels in bone regeneration

Human type H vessels are a sensitive biomarker of bone mass

Skeleton-vasculature Chain Reaction: a Novel Insight into the Mystery of Homeostasis

Advances in the understanding of the role of type-H vessels in the pathogenesis of osteoporosis

Role of angiocrine signals in bone development, homeostasis and disease

Sympathetic Neurostress Drives Osteoblastic Exosomal MiR‐21 Transfer to Disrupt Bone Homeostasis and Promote Osteopenia

Prostaglandin E2 mediates sensory nerve regulation of bone homeostasis

Specialized post-arterial capillaries facilitate adult bone remodelling

Type H vessels: functions in bone development and diseases

The role of vascular and lymphatic networks in bone and joint homeostasis and pathology

Sensory nerves regulate mesenchymal stromal cell lineage commitment by tuning sympathetic tones.

The roles of the sympathetic nervous system in osteoporotic diseases: A review of experimental and clinical studies.